iBio Inks 3D Bioprinting Agreement
August 19 2019 - 4:35PM
iBio, Inc. (NYSE AMERICAN:IBIO) today announced that it has entered
into a Master Services Agreement (“MSA”) with Lung Biotechnology
PBC, a subsidiary of United Therapeutics Corporation (NASDAQ:UTHR),
to produce recombinant human collagen (“rhCollagen”)-based bioink
for 3D bioprinted organ transplants. iBio will collaborate with
Lung Biotechnology PBC to scale-up production of rhCollagen in
tobacco plants using iBio’s
FastPharming™ System.
Under the MSA, the initial work to be performed
by iBio involves the development of a scalable purification process
for rhCollagen tailored to the biofabrication of lung scaffolds
that United Therapeutics licensed from CollPlant Biotechnologies
Inc. (NASDAQ:CLGN), as well as cGMP supply of the material for
clinical trials. Anticipating the need for commercial quantities of
rhCollagen-based bioinks, iBio envisions additional projects
focused upon process optimization and capacity expansion, the
latter of which will employ iBio’s Factory Solutions
capabilities.
“We’re pleased to have been selected by United
Therapeutics to help in the mission to fundamentally change access
to vital organ transplants for patients,” said Tom Isett, a member
of iBio’s Board of Directors. “The FastPharming
System is ideally suited to the production of bioinks, maturogens,
and other biologics for use in 3D bioprinting, so iBio will remain
committed to delivering its safety, quality, performance and cost
advantages to pioneers like United Therapeutics in the
transformational, cutting-edge biofabrication industry.”
Robert B. Kay, iBio’s Chairman and CEO commented
that, “Recent scientific breakthroughs in the emerging field of 3D
bioprinting have captured headlines worldwide. The decision by
United Therapeutics to work with iBio for the production of
rhCollagen bioinks in our FastPharming System
provides yet another opportunity to demonstrate the strength of our
platform, which has already been proven in the manufacture of
monoclonal antibodies, growth factors, fusion proteins, virus-like
particles, and other biologics. We’re looking forward to helping
United Therapeutics to successfully address the critical shortage
of transplantable lungs and other organs.”
About iBio, Inc.iBio is a
global leader in plant-based biopharmaceutical contract development
and cGMP manufacturing services. Our wholly-owned subsidiary,
iBio CDMO LLC, uses the FastPharming™ System
– which combines plant protein expression, automated hydroponics,
and glycan engineering technologies – to rapidly deliver gram
quantities of high-quality biologics for research or further
manufacturing uses from its 120,000 square foot facility in Bryan,
Texas. In addition to contract manufacturing, iBio also offers
process development, bioanalytical, and fill-finish services, along
with Factory Solutions for the design and build of facilities for
plant-made monoclonal antibodies, vaccines, bioinks and more. iBio
also uses its advanced manufacturing capabilities in the
development of its own therapeutic pipeline, including its lead
asset, CFB-03 for the treatment of fibrotic diseases. For more
information, visit www.ibioinc.com.
FORWARD-LOOKING
STATEMENTSSTATEMENTS INCLUDED IN THIS NEWS RELEASE RELATED
TO IBIO, INC. MAY CONSTITUTE FORWARD-LOOKING STATEMENTS WITHIN THE
MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995.
SUCH STATEMENTS INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES SUCH AS
COMPETITIVE FACTORS, TECHNOLOGICAL DEVELOPMENT, MARKET DEMAND, AND
THE COMPANY'S ABILITY TO OBTAIN NEW CONTRACTS AND ACCURATELY
ESTIMATE NET REVENUES DUE TO VARIABILITY IN SIZE, SCOPE, AND
DURATION OF PROJECTS. FURTHER INFORMATION ON POTENTIAL RISK FACTORS
THAT COULD AFFECT THE COMPANY'S FINANCIAL RESULTS CAN BE FOUND IN
THE COMPANY'S REPORTS FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION.
Contact:
Stephen KilmerInvestor Relations(646) 274-3580
skilmer@ibioinc.com
iBio (AMEX:IBIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
iBio (AMEX:IBIO)
Historical Stock Chart
From Sep 2023 to Sep 2024